Inhibition by O-desmethyltramadol of glutamatergic excitatory transmission in adult rat spinal substantia gelatinosa neurons.
Analgesics, Opioid
/ pharmacology
Animals
Drug Interactions
Excitatory Amino Acid Agents
/ pharmacology
Excitatory Postsynaptic Potentials
/ drug effects
Glutamic Acid
/ metabolism
In Vitro Techniques
Male
Narcotic Antagonists
/ pharmacology
Nerve Fibers
/ drug effects
Neurons
/ drug effects
Norepinephrine
/ pharmacology
Patch-Clamp Techniques
Peptides
/ pharmacology
Rats
Serotonin
/ pharmacology
Substantia Gelatinosa
/ cytology
Tramadol
/ analogs & derivatives
O-Desmethyltramadol
antinociception
glutamatergic synaptic transmission
patch-clamp
spinal substantia gelatinosa
μ-opioid receptor
Journal
Molecular pain
ISSN: 1744-8069
Titre abrégé: Mol Pain
Pays: United States
ID NLM: 101242662
Informations de publication
Date de publication:
Historique:
entrez:
26
2
2019
pubmed:
26
2
2019
medline:
18
5
2019
Statut:
ppublish
Résumé
To reveal cellular mechanisms for antinociception produced by clinically used tramadol, we investigated the effect of its metabolite O-desmethyltramadol (M1) on glutamatergic excitatory transmission in spinal dorsal horn lamina II (substantia gelatinosa; SG) neurons. The whole-cell patch-clamp technique was applied at a holding potential of -70 mV to SG neurons of an adult rat spinal cord slice with an attached dorsal root. Under the condition where a postsynaptic action of M1 was inhibited, M1 superfused for 2 min reduced the frequency of spontaneous excitatory postsynaptic current in a manner sensitive to a μ-opioid receptor antagonist CTAP; its amplitude and also a response of SG neurons to bath-applied AMPA were hardly affected. The presynaptic effect of M1 was different from that of noradrenaline or serotonin which was examined in the same neuron. M1 also reduced by almost the same extent the peak amplitudes of monosynaptic primary-afferent Aδ-fiber and C-fiber excitatory postsynaptic currents evoked by stimulating the dorsal root. These actions of M1 persisted for >10 min after its washout. These results indicate that M1 inhibits the quantal release of L-glutamate from nerve terminals by activating μ-opioid but not noradrenaline and serotonin receptors; this inhibition is comparable in extent between monosynaptic primary-afferent Aδ-fiber and C-fiber transmissions. Considering that the SG plays a pivotal role in regulating nociceptive transmission, the present findings could contribute to at least a part of the inhibitory action of tramadol on nociceptive transmission together with its hyperpolarizing effect as reported previously.
Identifiants
pubmed: 30799694
doi: 10.1177/1744806918824243
pmc: PMC6348506
doi:
Substances chimiques
Analgesics, Opioid
0
Excitatory Amino Acid Agents
0
Narcotic Antagonists
0
Peptides
0
O-demethyltramadol
2WA8F50C3F
Serotonin
333DO1RDJY
Tramadol
39J1LGJ30J
Glutamic Acid
3KX376GY7L
connective tissue-activating peptide
69344-77-0
Norepinephrine
X4W3ENH1CV
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1744806918824243Références
Neurosci Lett. 2011 Mar 3;490(3):191-5
pubmed: 21195741
Arzneimittelforschung. 2003;53(10):681-7
pubmed: 14650359
Chirality. 2007 Mar;19(3):190-6
pubmed: 17192836
Neuroscience. 2002;109(2):349-58
pubmed: 11801370
J Anesth. 2012 Apr;26(2):230-5
pubmed: 22038618
Br J Anaesth. 1997 Sep;79(3):352-6
pubmed: 9389855
Anesth Analg. 2012 Aug;115(2):443-9
pubmed: 22575568
Arzneimittelforschung. 1981;31(11):1932-43
pubmed: 7198474
J Neurophysiol. 2014 Mar;111(5):991-1007
pubmed: 24335211
Neuroscience. 2004;125(1):221-31
pubmed: 15051161
PLoS One. 2015 May 01;10(5):e0125147
pubmed: 25933213
Brain Res Bull. 1999 Jan 15;48(2):129-41
pubmed: 10230704
Neuroscience. 2006;139(3):1095-105
pubmed: 16515840
J Anesth. 2015 Jun;29(3):475-479
pubmed: 25394761
J Pharmacol Exp Ther. 1992 Jan;260(1):275-85
pubmed: 1309873
Anesthesiology. 2003 Mar;98(3):682-9
pubmed: 12606912
Br J Pharmacol. 1992 Jan;105(1):147-51
pubmed: 1596676
Naunyn Schmiedebergs Arch Pharmacol. 2000 Aug;362(2):116-21
pubmed: 10961373
Biochem Pharmacol. 1994 Jun 15;47(12):2289-93
pubmed: 8031323
Brain Res. 1990 Jun 25;521(1-2):15-22
pubmed: 2169958
J Neurophysiol. 2011 May;105(5):2337-49
pubmed: 21411568
Arzneimittelforschung. 1988 Jul;38(7):877-80
pubmed: 2849950
Br J Pharmacol. 2005 Jul;145(5):602-7
pubmed: 15834442
Anesthesiology. 2007 Nov;107(5):807-12
pubmed: 18073556
J Pharmacol Sci. 2014;126(2):136-45
pubmed: 25252797
J Neurosci. 2000 Aug 15;20(16):6302-8
pubmed: 10934282
J Physiol. 1999 Aug 1;518 ( Pt 3):803-13
pubmed: 10420016
Arzneimittelforschung. 1996 Nov;46(11):1029-36
pubmed: 8955860
Br J Pharmacol. 1993 Mar;108(3):806-11
pubmed: 8467366
Brain Res Dev Brain Res. 1998 Jun 15;108(1-2):239-54
pubmed: 9693800
Brain Res. 1991 May 31;550(1):77-85
pubmed: 1653636
Naunyn Schmiedebergs Arch Pharmacol. 2015 Oct;388(10):999-1007
pubmed: 26292636